Search competencies and applied modules
Ibogaine safety and risk management
Pharmacology and time course
Ibogaine Safety and Risk Management
Educational material; not a treatment relationship.
Pharmacokinetic and phenomenological timeline
Ibogaine exposure, the inward experience, and physical recovery do not follow one shared clock. Read them together while keeping the limits of each source in view.
Onset
First minutes to hours
Pharmacokinetics
Ibogaine is absorbed and converted to active noribogaine, principally through CYP2D6. In a model of 14 people with opioid use disorder, median time to peak ibogaine concentration was 0.62 hours. This is a plasma measurement, not the time of peak subjective intensity.
Absorption and the first changes
Mash and colleagues reported initial visual effects around 30 to 45 minutes after oral ibogaine in their treatment cohort. Altered sound, bodily sensations, and changes in thinking may accompany imagery. Other accounts describe different onsets or little visual content.
Care focus
Agree on a simple way to call for assistance before absorption begins. Keep a familiar voice available, explain necessary contact, and have movement and toileting support ready. Record onset and observed changes without making the person repeatedly narrate the experience.
Responsibility: clinical team and facilitator. Setting: medically supervised care. Full care guidance and evidence
Acute experience
Several hours; highly variable
Pharmacokinetics
Parent drug and metabolite overlap. In the same 2024 model, median noribogaine peak occurred at 7.57 hours, with an interquartile range of 5.93 to 10.4 hours. Ibogaine concentrations were associated with QTc change and ataxia; the model does not predict an individual’s experience.
Inward absorption and bodily vulnerability
In Mash’s cohort, many people described a dreamlike period lasting 4 to 8 hours. Accounts include autobiographical scenes, symbolic or frightening imagery, and altered time or self perception. Others report little imagery. These are possible experiences, not milestones required for benefit.
Care focus
Keep monitoring and relational support staffed as distinct responsibilities. Someone can appear still while intensely absorbed and physically unsteady. Reduce unnecessary movement and stimulation, protect dignity during emesis or toileting, and offer orientation without directing the narrative. Assess a change in attention, responsiveness, or physiology rather than explaining it away as a phase.
Responsibility: clinical team and facilitator. Setting: medically supervised care. Full care guidance and evidence
As intensity eases
Later hours into the next day
Pharmacokinetics
Noribogaine exposure can continue after the most vivid effects settle. Metabolism and interacting medicines change the duration of exposure. The end of imagery does not establish that cardiac or coordination effects have resolved.
A quieter experience is a transition
Some accounts move from vivid scenes toward quieter reflection; fatigue, sensitivity, or wakefulness may remain. There may be no clear dividing line. Schenberg’s qualitative work describes substantial physical and emotional difficulty alongside reflection, rather than one uniformly peaceful resolution.
Care focus
Carry both the participant’s account and objective findings into the handoff. Ask about comfort, orientation, nausea, sleep, and intake. Offer space to speak without turning every recollection into therapy. Readiness to stand, eat, reduce monitoring, or move to another setting needs its own assessment.
Responsibility: clinical team and facilitator. Setting: medically supervised care. Full care guidance and evidence
Following days
Recovery and continuing care
Pharmacokinetics
After direct noribogaine administration in healthy volunteers, mean elimination half lives ranged from 28 to 49 hours across dose groups. That study is different from ibogaine treatment. A half life describes concentration decline; it is not a discharge deadline or a duration of psychological benefit.
Persistent drug activity and changing needs
Sleep, energy, mood, certainty, and craving may change after the acute session. People need room for relief, disappointment, or mixed feelings without having those reactions labeled as success or failure. The guide does not assign everyone a fixed “gray day” or an afterglow.
Care focus
Base discharge on clinical and functional readiness and a workable follow up plan. Review sleep, food and fluids, medications, mood, substance use risk, transport, and available support. Help the participant revisit important decisions after rest and in the context of ordinary life.
Responsibility: clinical team and facilitator. Setting: medically supervised care. Full care guidance and evidence